论文部分内容阅读
背景与目的:伊立替康联合氟尿嘧啶/亚叶酸钙方案为晚期大肠癌一线治疗的标准方案。本研究观察伊立替康联合氟尿嘧啶/亚叶酸钙双周(CPT-11+5FU/LV双周FOLFIR I)方案一线治疗晚期大肠癌的客观有效率及不良反应。方法:2001年5月—2005年3月,37例晚期大肠癌患者接受FOLFIR I方案一线治疗。化疗剂量为CPT-11 180 mg/m2静脉点滴第1天,亚叶酸钙(LV)200 mg/m2静脉点滴第1、2天,5-FU 400 mg/m2静推第1、2天,5-FU 600 mg/m2持续泵注44小时第1、2天,14天为1周期。结果:36例可评价疗效患者有效率为41.7%。Ⅲ/Ⅳ度骨髓抑制发生率占总人数的35.1%和8.1%,4例患者出现中性粒细胞减少性发热。Ⅲ度迟发性腹泻发生率为8.1%。结论:伊立替康联合氟尿嘧啶/亚叶酸钙双周方案(FOLFIR I)是一线治疗晚期大肠癌安全而有效的方案。
BACKGROUND & AIM: The irinotecan plus fluorouracil / leucovorin regimen is a standard protocol for first-line treatment of advanced colorectal cancer. This study was to observe the objective response rate and side effects of irinotecan combined with fluorouracil / leucovorin bilaterally (CPT-11 + 5FU / LV bi-weekly FOLFIR I) in the first-line treatment of advanced colorectal cancer. Methods: From May 2001 to March 2005, 37 patients with advanced colorectal cancer underwent FOLFIR I regimen. Chemotherapy dose was CPT-11 180 mg / m2 intravenous drip 1 day, leucovorin (LV) 200 mg / m2 intravenous drip 1,2 days, 5-FU 400 mg / m2 intravenous push 1,2 days, 5 -FU 600 mg / m2 Continuous Pumping 44 hours Day 1, Day 2, 14 days for 1 cycle. Results: The effective rate of 36 evaluable patients was 41.7%. Ⅲ / Ⅳ degree of myelosuppression accounted for 35.1% of the total number and 8.1%, 4 patients showed neutropenic fever. Ⅲ degree of delayed diarrhea incidence of 8.1%. Conclusion: The combination of irinotecan and fluorouracil / leucovorin double-weekly (FOLFIR I) is a safe and effective first-line therapy for advanced colorectal cancer.